The success of mRNA vaccines against Covid-19 and the approval of several RNA-based drugs in recent years have made RNA medicine a reality. In particular, RNA interference (RNAi), a natural mechanism that silences target genes with small interfering RNAs, has attracted considerable attention as a therapeutic strategy for genetically impaired conditions that are intractable to conventional small-molecule and antibody approaches. However, their clinical successes have been limited to rare genetic disorders associated with liver diseases due to limited hepatic delivery systems such as lipid nanoparticles and N-acetylgalactosamine. To safely and efficiently deliver RNAi therapeutics beyond the liver, we designed various RNA conjugates using different endogenous/exogenous proteins and peptides. These carrier-free RNA conjugate delivery systems provide a simple and widely applicable platform for the systemic delivery of various RNAi therapeutics and offer safe and effective tumor-targeted RNAi-based therapies.